United Therapeutics Corp (NASDAQ:UTHR) Chairperson and CEO Martine A. Rothblatt executed a series of stock transactions on April 27, 2026, involving the sale of 9,500 shares of common stock for approximately $5.4 million. The disposal was part of a structured process that began with the exercise of 9,500 stock options. These options were exercised at a price point of $146.03 per share, totaling an investment of $1,387,285. The specific options used in this transaction had an original exercise date of March 15, 2020, and are set to expire on March 15, 2027.
Transaction Structure and Timing
The movement of these shares was not an isolated market event but was conducted under a pre-arranged 10b5-1 trading plan. This regulatory framework allows insiders to schedule trades in advance to avoid conflicts regarding non-public information. Ms. Rothblatt adopted this specific plan on November 7, 2025. The plan is designed to remain active until either December 31, 2026, is reached or until a total of 1,734,410 stock options (which all share an expiration date of March 17, 2027) have been exercised.
The sale was not executed in a single block but through multiple trades. These transactions were completed at weighted average prices that spanned from $565.7493 to $572.2183 per share. Per standard reporting procedures, the individual involved has committed to providing comprehensive data regarding the exact number of shares and the specific prices for each transaction upon request.
Current Equity Holdings and Financial Profile
Following this latest round of transactions, Ms. Rothblatt maintains a direct holding of 40,513 shares of United Therapeutics common stock. Her total interest in the company is further reflected through various indirect holdings. These include 166 shares held by her spouse, as well as several holdings through family trusts:
- 324,443 shares are held in trusts where Ms. Rothblatt serves as a beneficiary and shares investment power.
- 258,117 shares are held in trusts where her spouse acts as the sole or co-trustee.
- 45,596 shares are held in trusts where her spouse shares investment power.
- 10,962 shares are held in trusts where she serves as the sole or co-trustee.
Additionally, Ms. Rothblatt holds derivative interests in the form of stock options, which total 110,288 shares following this transaction.
From a fundamental perspective, United Therapeutics reports gross profit margins of 88% and maintains a P/E ratio of 20.46. While the stock has seen significant growth, some analyses suggest that the current market price may be overvalued relative to its calculated Fair Value.
Operational Developments and Analyst Outlook
The company continues to progress in its clinical and regulatory endeavors. The U.S. Food and Drug Administration recently granted Regenerative Medicine Advanced Therapy designation to miroliverELAP, an investigational device intended for temporary liver support in patients experiencing acute liver failure. Furthermore, United Therapeutics is scheduled to participate in the International Society for Heart and Lung Transplantation’s annual meeting, where it will present 11 data sets. These presentations involve interim analyses from the ARTISAN and PHINDER studies, which focus on arterial hypertension and pulmonary hypertension.
Wall Street analysts have provided varying perspectives on the company's valuation and potential:
- Raymond James initiated coverage with an Outperform rating and a $700 price target, pointing to the possibility of Tyvaso achieving peak sales exceeding $5 billion in the idiopathic pulmonary fibrosis market.
- H.C. Wainwright maintained a Buy rating and increased its price target to $660, citing data from the TETON-1 trial for Tyvaso.
- BofA Securities updated its price target to $626 while maintaining a Neutral rating, following results from Phase 3 trials.